ArriVent BioPharma, Inc. (AVBP) stock forecast and price target
Price $13.01 · data as of November 13, 2026
12-month price target
Average target$26.40
Upside / downside+102.9%
Analysts10
ConsensusStrong buy
Low $22.00Average $26.40High $30.00
Gold marker: average target · white marker: today’s price ($13.01)
Analyst ratings
Strong buy 0Buy 11Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-3.94 | +8.7% | $5M |
| Next fiscal year ends December 31, 2027 | $-3.62 | +8.1% | $7M |
| Next quarter ends December 31, 2026 | $-1.01 | −29.0% | $0 |
| Quarter after ends December 31, 2026 | $-0.95 | −21.8% | $3M |
Consensus of the analysts covering ArriVent BioPharma, updated daily. In the last 30 days 5 estimates were raised and 0 lowered.
Frequently asked questions
What is the ArriVent BioPharma stock price target?
The average 12-month target from 10 analysts is $26.40, 102.9% above the current price of $13.01 Targets range from $22.00 to $30.00.
Is ArriVent BioPharma a buy according to analysts?
The consensus rating is “Strong buy” (11 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is ArriVent BioPharma expected to earn?
Analysts expect EPS of $-3.94 for the fiscal year ending December 31, 2026 and $-3.62 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.